At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 60 enrolled
Drug / intervention
Telavancin +1 moredrug
Likely dose
Telavancin 10 mg/kg/day IV every 24 hours for up to 14 daysAI-extracted
Key inclusion· 1
- ✓Documented S. aureus bacteremia
Key exclusion· 1
- ✕More than 72 hours of potentially effective systemic antistaphylococcal therapy within 7 days prior to randomization (including antistaphylococcal penicillins, cephalosporins, fluoroquinolones, glycopeptides, or linezolid)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Televancin (TD-6424) for Treatment of Uncomplicated Staphylococcus Aureus Bacteremia
In Brief
A Phase 2 clinical trial evaluating Telavancin and Vancomycin, nafcillin, oxacillin, or cloxacillin for Gram-Positive Bacterial Infections. Completed, enrolled 60 participants across 1 site.
Detailed Summary
The purpose of this study is to determine whether telavancin (TD-6424, ARBELIC) can be safety administered to patients with bloodstream infections and whether telavancin is effective in treating these infections.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGram-Positive Bacterial Infections
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2003
Enrollment StartAug 2003
Primary CompletionAug 2006
TodayJul 2026
First PostedJun 12, 2003
Enrollment StartAug 1, 2003
Primary CompletionAug 1, 2006
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 23.1 years ago
Interventions
Telavancindrug
Telavancin 10mg/kg/day IV every 24 hrs for up to 14 days
Vancomycin, nafcillin, oxacillin, or cloxacillindrug
Vancomycin 1 Gram every 12 hr IV (intravenously) OR nafcillin, oxacillin, or cloxacillin 2 Grams every 6 hr IV (intravenously) for up to 14 days.